

Pre-operative Hypercarbia and Length of Hospital Stay at the Time of Growing Device Implantation and Spine Fusion in Early Onset Scoliosis

G. Redding, V. Bompadre, W. Krengel, K. White
Seattle Children's Hospital
University of Washington School of Medicine
Seattle, Washington, USA

Background

- Children with EOS often have restrictive lung disease, respiratory muscle dysfunction, and hypoxemia during sleep.
- Pre-operative risk assessment for post-operative respiratory complications in this group of patients is not standardized.
- Specific pulmonary measures that correlate with post-operative hospital length of stay are limited to forced vital capacity (FVC); FVC values <40% predicted are associated with longer hospital stay for patients with AIS.

Published EOS/TIS LOS is longer than with AIS with FVC <40%

<i>N</i>	<i>Age</i>	<i>FVC</i>	<i>Procedure</i>	<i>LOS</i>	<i>% Pulm Comp</i>
EOS Patients					
20	38mo	-	VEPTR implant	11 (5-29)	-
10	12y	-	VEPTR	-	4/10
29	8yr	-	VEPTR implant	6.7	6/32
AIS Patients					
183	6-62	60-80%	FUSION	-	3/110
		40-60%		-	4/54
		<40%			6/19

Questions & Metrics

1. What are the pre-operative attributes of children with TIS/EOS as defined by:
 - Increased hospital stay due to pulmonary reasons
 - Increased ICU stay due to pulmonary reasons
2. Can patients with longer LOS be identified pre-operatively by assessment of hypercarbia, as measured by capillary PCO₂ or metabolic compensation for chronic CO₂ retention, i.e. serum total CO content, obtained with electrolytes?

Methodology

- Retrospective chart review of 52 children with EOS undergoing either initial Growing Device implantation and/or Spine Fusion
- Pre-operative documentation of CO2 status; type of surgery, hospital LOS, ICU LOS, pulmonary complication
- No primary lung disease, e.g. asthma, known pulmonary hypoplasia
- No history of surgery for congenital heart disease

Results

- 20/41 (49%) patients with EOS had CO₂ assessments pre-operatively at the time of device insertion.
- 10/18 (56%) had pre-op CO₂ assessments at the time of spine fusion.
- 21 (13 implant + 8 fusion) had PCO₂ measurements; 17 (9 implant + 8 fusion) had total CO₂ content (electrolyte) measures.

Results (cont'd)

- Pcap CO₂ was normal (<45 mmHg) in all children pre-operatively at device implantation; but elevated in 4/8 (50%) at the time of fusion.
- Total serum CO₂ content was high (>25 meq/dl) in 5/10 (50%) at device implantation and 7/8 (88%) at time of fusion.

Results (cont'd)

- Hospital LOS for device implantation was median of 6.5 days (range 4-37 days); for fusion, LOS was 7 days (range 5-16 days)
- ICU LOS for device implantation was a median of 2 days (range=1-14 days); for fusion ICU LOS was 2 days (range 1-6 days).
- Neither Pcap CO₂ nor serum CO₂ content correlated with ICU or hospital LOS.

Conclusions

- Serum CO₂ content is more often abnormal than PcapCO₂ values pre-operatively, reflecting chronic CO₂ retention, perhaps during sleep.
- Hospital LOS and ICU LOS were similar for device implantation and spine fusion.
- CO₂ measurements have not been included routinely in pre-operative assessments in our center.

Conclusions (cont'd)

- Pre-operative measures that predict post-operative outcomes for children with EOS at the time of device implantation and at the time of spine fusion remain to be determined.
- Pre-op CO₂ status did not correlate with LOS in this single-center review.
- Serum CO₂ content seems more likely to be useful than PcapCO₂ but will require greater numbers to determine its utility.